If you only glanced at headlines this year, Ionis Pharmaceuticals looked like a clear win, with fresh approvals, upbeat guidance and bullish talk of blockbuster launches. Holding Ionis Pharmaceuticals from the start of the year would have meant a 46.8% loss, including dividends. If you had been deciding on 1 January whether to back that story, how much of the later setback was already hinted at in the early financial strain and pipeline risks?
On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.
The easy part of this move is behind Ionis Pharmaceuticals. Zero in on 32 high quality undervalued stocks for companies trading below our estimates.
The Two Stories Ionis Investors Were Really Choosing Between
The shares cost US$79.11 at the start of the period, and anyone looking at Ionis Pharmaceuticals then had to decide which story felt more convincing.
The bullish Narrative pointed to a Fair Value of US$96, built on revenue growth of 27.7% a year and a shift from a loss to a 19.0% profit margin within three years. That view leaned on expectations of consecutive blockbuster launches and a powerful antisense platform.
The more cautious Narrative put Fair Value at US$69.48 and assumed revenue growth of 17.3% and a 14.2% profit margin. It highlighted pressure from pricing cuts as Olezarsen moved into broader indications and the risk that a few late stage drugs carried outsized regulatory and execution exposure.
What The Results Changed For The Ionis Pharmaceuticals Thesis
The key development for Ionis Pharmaceuticals was the sharp setback for eplontersen, where the CARDIO-TTRansform trial missed its primary endpoint in transthyretin cardiomyopathy. That undercut the bullish idea that late stage programs would reliably convert to high margin blockbusters. At the same time, Q2 2026 results showed revenue and net income both fell and net margin moved from 27.3% to a loss of 42.8%. Together, the evidence leaned toward the cautious case.
The lesson here is simple. When a story leans heavily on multiple future launches, treat two figures as non negotiable checks: first, watch each pivotal trial outcome against the original label ambitions; second, track whether reported net margin is actually moving toward the promised level rather than away from it.
What You Are Paying For In Ionis Pharmaceuticals Today
Ionis Pharmaceuticals now trades at US$42.38, well below where the year began. The selected Narrative sees Fair Value above that level and anchors its argument in neurology, renal disease and royalty streams rather than broad cardiometabolic wins.
On that view, a buyer today is effectively assuming that recently approved therapies convert into durable usage and reimbursement across targeted rare disease populations.
"Key Takeaways: Bullish analysts expect Ionis Pharmaceuticals to extend its antisense leadership into larger cardiometabolic and neurology markets as Tryngolza, DAWNZERA and ZANVASTRO build on a growing base of approved therapies. The main thing that has to go right is that Ionis converts its recent approvals and late-stage wins in areas like severe hypertriglyceridemia, Alexander disease, IgA nephropathy and FUS-ALS into durable adoption and reimbursement across targeted patient populations."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Another Way To Play Ionis
Ionis Pharmaceuticals focuses on high risk research and concentrated drug bets. You might also consider a business operating one step away.
Drug discovery often relies on a broad pipeline, not only a few flagship projects. One large healthcare group is investing heavily in new medicines and device platforms.
This operation spreads its work across several treatment areas. Cancer, immune disorders, brain health and heart disease all sit on its development list.
For you, the question remains simple. How might this wider mix of therapies and medical procedures reshape risk compared with Ionis?
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 29% above its price
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com